Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Relatlimab is a monoclonal antibody designed for the treatment of melanoma. It is used in combination with nivolumab to treat melanoma.
History, Names & Overview
Explore the main themes, entities and connections around Relatlimab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
lag-3 nivolumab combination melanoma treatment pardoll new immune checkpoint cancer antibody lymphocyte activation gene-3 names drew 2022 inhibitor cells proteins
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Relatlimab | ATC code | None | 1.00 | infobox |
| Relatlimab | CAS Number | 1673516-98-7 | 1.00 | infobox |
| Relatlimab | Drug class | Antineoplastic | 1.00 | infobox |
| Relatlimab | DrugBank | DB14851 | 1.00 | infobox |
| Relatlimab | Formula | C6472H9922N1710O2024S38 | 1.00 | infobox |
| Relatlimab | KEGG | D11350 | 1.00 | infobox |
| Relatlimab | Legal status | CA: ℞-only | 1.00 | infobox |
| Relatlimab | Legal status | US: ℞-only only in combination with nivolumab | 1.00 | infobox |
| Relatlimab | License data | US DailyMed: Relatlimab | 1.00 | infobox |
| Relatlimab | Molar mass | 145288.79 g·mol−1 | 1.00 | infobox |
| Relatlimab | Other names | BMS-986016, relatlimab-rmbw | 1.00 | infobox |
| Relatlimab | Routes of administration | Intravenous | 1.00 | infobox |
| Relatlimab | Source | Human | 1.00 | infobox |
| Relatlimab | Target | Lymphocyte activation gene-3 (LAG-3) | 1.00 | infobox |
| Relatlimab | Type | Whole antibody | 1.00 | infobox |
| Relatlimab | UNII | AF75XOF6W3 | 1.00 | infobox |
| Relatlimab | is a | monoclonal antibody designed for the treatment of melanoma | 0.90 | text |
| Relatlimab | is a | Lymphocyte activation gene-3 | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.